Clinical Trial Update: A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating PRX-00023 for generalized anxiety disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PRX-00023

Snippet

Sponsor: Epix Pharmaceuticals, Inc. | Conditions: Anxiety Disorders | Phase 3 | Status: COMPLETED